Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ONXX -- Ignore unavailable to you. Want to Upgrade?

To: r.edwards who wrote (302)	4/15/1999 11:02:00 AM
From: scaram(o)uche	Read Replies (1) \| Respond to of 810

The admission that tumors with wild type p53 can be infected by the E1B-deleted virus, and the proposed mechanism, is new. Moreover, the company presented a variety of other new material at the meeting (efforts to engineer more effective viral isolates, etc.). Next, you are saying that you would assign a research premium of $20 million to a company that has complete remissions in head and neck, a development candidate with Bayer for Ras, and several other preclinical programs of interest. No wonder third-tier is whacked. The world is now made up of insane folks.